Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
Background: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review aimed to investigate the impact of sex on clinical o...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241306940 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063321476104192 |
|---|---|
| author | Rita Leporati Édouard Auclin Daniel Morchón Miquel Ferriol-Galmés Juan Carlos Laguna Teresa Gorria Cristina Teixidó Maria Aranzazu Amores Paolo Ambrosini Dolores Isla Giuseppe Lo Russo Laura Mezquita |
| author_facet | Rita Leporati Édouard Auclin Daniel Morchón Miquel Ferriol-Galmés Juan Carlos Laguna Teresa Gorria Cristina Teixidó Maria Aranzazu Amores Paolo Ambrosini Dolores Isla Giuseppe Lo Russo Laura Mezquita |
| author_sort | Rita Leporati |
| collection | DOAJ |
| description | Background: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review aimed to investigate the impact of sex on clinical outcomes in patients with NSCLC harboring driver fusions treated with targeted therapies enrolled in clinical trials. Data sources and methods: A comprehensive literature search was conducted using PubMed, Embase, and relevant conference abstracts to identify phase III randomized and early clinical trials that reported sex-specific data, including progression-free survival (PFS), overall survival (OS), overall response rate, and adverse events (AEs), in patients with fusion-positive NSCLC treated with tyrosine kinase inhibitors (TKIs). Results: This review involved 10 studies reporting PFS data and 3 studies with OS data, focusing on first-line treatments for ALK fusion (9 studies) and RET fusion-positive (1 study) NSCLC. Pooled analysis of hazard ratios (HRs) for PFS and OS in ALK inhibitors trials revealed no significant differences in survival outcomes based on sex. Additionally, none of the studies provided data on sex-based differences in response rates or toxicities, highlighting a significant knowledge gap regarding the impact of sex on secondary outcomes in targeted therapy. Conclusion: This review found no significant sex-related differences in survival outcomes among patients treated with ALK inhibitors. However, the lack of data on sex-specific response and toxicity emphasizes the need for future research to better understand the role of sex in modulating treatment outcomes and treatment decisions with TKIs. |
| format | Article |
| id | doaj-art-77f74f83c32c4cfaa6526f215542c0db |
| institution | DOAJ |
| issn | 1758-8359 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-77f74f83c32c4cfaa6526f215542c0db2025-08-20T02:49:39ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-12-011610.1177/17588359241306940Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic reviewRita LeporatiÉdouard AuclinDaniel MorchónMiquel Ferriol-GalmésJuan Carlos LagunaTeresa GorriaCristina TeixidóMaria Aranzazu AmoresPaolo AmbrosiniDolores IslaGiuseppe Lo RussoLaura MezquitaBackground: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review aimed to investigate the impact of sex on clinical outcomes in patients with NSCLC harboring driver fusions treated with targeted therapies enrolled in clinical trials. Data sources and methods: A comprehensive literature search was conducted using PubMed, Embase, and relevant conference abstracts to identify phase III randomized and early clinical trials that reported sex-specific data, including progression-free survival (PFS), overall survival (OS), overall response rate, and adverse events (AEs), in patients with fusion-positive NSCLC treated with tyrosine kinase inhibitors (TKIs). Results: This review involved 10 studies reporting PFS data and 3 studies with OS data, focusing on first-line treatments for ALK fusion (9 studies) and RET fusion-positive (1 study) NSCLC. Pooled analysis of hazard ratios (HRs) for PFS and OS in ALK inhibitors trials revealed no significant differences in survival outcomes based on sex. Additionally, none of the studies provided data on sex-based differences in response rates or toxicities, highlighting a significant knowledge gap regarding the impact of sex on secondary outcomes in targeted therapy. Conclusion: This review found no significant sex-related differences in survival outcomes among patients treated with ALK inhibitors. However, the lack of data on sex-specific response and toxicity emphasizes the need for future research to better understand the role of sex in modulating treatment outcomes and treatment decisions with TKIs.https://doi.org/10.1177/17588359241306940 |
| spellingShingle | Rita Leporati Édouard Auclin Daniel Morchón Miquel Ferriol-Galmés Juan Carlos Laguna Teresa Gorria Cristina Teixidó Maria Aranzazu Amores Paolo Ambrosini Dolores Isla Giuseppe Lo Russo Laura Mezquita Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review Therapeutic Advances in Medical Oncology |
| title | Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review |
| title_full | Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review |
| title_fullStr | Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review |
| title_full_unstemmed | Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review |
| title_short | Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review |
| title_sort | sex differences in patients with non small cell lung cancer harboring driver fusions treated with tyrosine kinase inhibitors a systematic review |
| url | https://doi.org/10.1177/17588359241306940 |
| work_keys_str_mv | AT ritaleporati sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT edouardauclin sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT danielmorchon sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT miquelferriolgalmes sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT juancarloslaguna sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT teresagorria sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT cristinateixido sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT mariaaranzazuamores sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT paoloambrosini sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT doloresisla sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT giuseppelorusso sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview AT lauramezquita sexdifferencesinpatientswithnonsmallcelllungcancerharboringdriverfusionstreatedwithtyrosinekinaseinhibitorsasystematicreview |